Cardiff Lexington Corporation has announced its financial results for the second quarter ended June 30, 2025. The company reported a significant 89.5% increase in total revenue, reaching $2.8 million compared to the same period in 2024. Gross profit surged by 149.8% to $1.7 million, while income from continuing operations saw a dramatic rise of 482.3% to $610,000 compared to the second quarter of 2024. In terms of financial health, Cardiff Lexington's non-GAAP adjusted EBITDA, excluding interest expense, increased by 181.1% to $1.3 million, up from $446,000 in the first six months of 2024. The company's cash position was $560,000 as of June 30, 2025, with total assets climbing 10.8% to $26.5 million. Total stockholders' equity stood at $754,000. The company is experiencing strong demand, particularly at its 12 Nova Ortho & Spine locations in Florida and Georgia. Cardiff Lexington is focusing on expanding its footprint through organic growth and strategic mergers and acquisitions, as well as increasing operating capacity to drive long-term growth and value for shareholders.